The new data, released at the ASCO annual meeting, will help inform treatment decisions for many women with early-stage breast cancer.
Posted: January 8, Joint pain caused by aromatase inhibitors in postmenopausal women with breast cancer can cause some women to stop taking the drugs. Posted: March 1, Testing for genetic mutations strongly associated with an increased risk of breast cancer has risen dramatically among women younger than age 40 who are diagnosed with the disease, according to a new study.
Posted: September 28, Initial findings from the Trial Assigning Individualized Options for Treatment, or TAILORx, finds that women with early-stage hormone receptor-positive breast cancer have a low risk of recurrence based on a test for the expression of 21 genes.
The rate of DNA and RNA mutations can be too high under some conditions such as; unhealthy emironment due to radiation, chemicals, etc.
Posted: September 4, Arsenic trioxide and retinoic acid work together to target the master regulator protein Pin1, a new study shows.
Consequently, survival rates for breast cancer have improved significantly, particularly in younger women.
Posted: August 20, FDA has expanded the approved uses of ribociclib Kisqali for women with advanced breast cancer, including new uses in pre- and postmenopausal women. Posted: October 3, When given at the same time, two immune checkpoint inhibitors were ineffective against breast cancer growth in mice, a new study found.
A new study uses a bone marrow transplant drug, plerixafor, to break down this barrier and improve the efficacy of immune checkpoint inhibitors in animal models of breast cancer. Posted: December 4, Researchers are testing a topical-gel form of the drug tamoxifen to see if it can help prevent breast cancer as effectively as the oral form of the drug but with fewer side effects.
Posted: August 23, FDA has approved neratinib for patients with early-stage HER2-positive breast cancer who have finished at least 1 year of adjuvant therapy with trastuzumab. Posted: March 11, The build-up of connective tissue around some types of cancer can act as a barrier to immunotherapy.